

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**  
**{Box}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Utertab 2000 mg intrauterine tablet for cattle  
Tetracycline hydrochloride

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each intrauterine tablet contains:

**Active substance:**

Tetracycline hydrochloride 2000.0 mg  
(equivalent to 1848.2 mg tetracycline)

**3. PHARMACEUTICAL FORM**

Intrauterine tablet

**4. PACKAGE SIZE**

10, 20, 50, 100, 200, 300, 400 or 500 tablets

**5. TARGET SPECIES**

Cattle (lactating cow)

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

For intrauterine use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Withdrawal period:

Cattle:	Meat and offal	10 days
	Milk	96 hours

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

aniMedica GmbH  
Im Südfeld 9  
48308 Senden-Bösensell  
Germany

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 24745/4025

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

{Blister}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Utertab 2000 mg intrauterine tablet for cattle  
Tetracycline hydrochloride

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

aniMedica GmbH

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

<Batch><Lot> {number}

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**

Utertab 2000 mg intrauterine tablet for cattle

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER  
AND OF THE MANUFACTURING AUTHORISATION HOLDER  
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

aniMedica GmbH  
Im Südfeld 9  
48308 Senden-Bösensell  
Germany

Manufacturer responsible for batch release:

aniMedica GmbH  
Im Südfeld 9  
48308 Senden-Bösensell  
Germany

aniMedica Herstellungs GmbH  
Im Südfeld 9  
48308 Senden-Bösensell  
Germany

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Utertab 2000 mg intrauterine tablet for cattle  
Tetracycline hydrochloride

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER  
INGREDIENT(S)**

Each intrauterine tablet contains:

**Active substance:**

Tetracycline hydrochloride 2000.0 mg  
(equivalent to 1848.2 mg tetracycline)

Yellow tablet with central score. The score line is not intended to divide the tablet into equal doses.

**4. INDICATION(S)**

For treatment and prevention of post parturient disorders in cattle: for administration following retained foetal membranes and endometritis caused by pathogens susceptible to tetracycline as well as after severe obstetrical procedures (fetotomy, caesarean section).

## **5. CONTRAINDICATIONS**

Do not use in infections caused by pathogens resistant to tetracycline.

Do not use in known cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in severe kidney or liver disorders.

## **6. ADVERSE REACTIONS**

Occurrence of renal disorders is enhanced in dehydrated animals.

Tetracycline can cause damage to the liver.

Photodermatitis often occurs in areas of sparsely pigmented skin if these are exposed to intensive sunlight.

Allergic reactions are rare.

In case of allergic or anaphylactic reactions, discontinue treatment immediately.

Allergic reactions can be treated parenterally with glucocorticoids and antihistamines.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated )
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}.

## **7. TARGET SPECIES**

Cattle (lactating cow)

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Intrauterine use.

Cows:

2 g tetracycline hydrochloride / cow / day  
equivalent to 1 tablet / cow /day

Treat one to three times at intervals of 1 up to 2 days.

## **9. ADVICE ON CORRECT ADMINISTRATION**

None.



## **10. WITHDRAWAL PERIOD**

Cattle: Meat and offal 10 days  
Milk 96 hours

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after {abbreviation used for expiry date}. The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals:

Whenever possible, the product should only be used based on susceptibility testing. Official, national and regional antimicrobial policies should be taken into account when the product is used. Milk from treated cows should not be fed to calves up to the end of the milk withdrawal period, except during the colostrum phase, due to potential for selection of resistance in intestinal flora of calves.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This product may cause sensitisation. Avoid direct contact with the skin or the mucous membranes.

Gloves should be worn when handling the veterinary medicinal product.

Wash hands after use.

### Use during pregnancy, lactation or lay

The product is specifically for use in the post-parturition period.

### Interaction with other medicinal products and other forms of interaction:

There is a potential antagonism between tetracyclines and antibiotics with bactericidal action.

### Overdose (symptoms, emergency procedures, antidotes), if necessary

Overdose is not expected because each tablet represents a single dose. Please refer to section "Adverse reactions".

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.


**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

**15. OTHER INFORMATION**

Pack sizes:

Cardboard box of 2, 4, 10, 20, 40, 60, 80, 100 blisters of 5 intrauterine tablets.  
Corresponding to pack sizes of 10, 20, 50, 100, 200, 300, 400 and 500 intrauterine tablets. Not all pack sizes may be marketed.

To be supplied only on veterinary prescription.

A handwritten signature in black ink, consisting of several loops and a final horizontal stroke.

Approved: 12 December 2022